MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG- 3095)

• IRAS ID

  1008605

• Contact name

  - -

• Contact email

  N/A

• Sponsor organisation

  Merck Sharp & Dohme LLC

• Research summary

  Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment. EC is a type of cancer that starts in the tissues inside the uterus (womb). EC may be treated with chemotherapy and immunotherapy. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Immunotherapy is a treatment that helps the immune system fight cancer.

  MK-2870, the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread.

  This clinical study will compare MK-2870 to chemotherapy. The goal of the study is to learn if people who receive MK-2870 live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

  710 people with EC will be in this study. They will be at least 18 years old and:
  • Have previously received immunotherapy and certain chemotherapy to treat EC
  • Not have certain heart diseases

  People will have an equal chance of receiving either:
  • MK-2870, the study medicine, given once every 2 weeks
  • Chemotherapy of the researcher’s choice, which is either:
  o Doxorubicin, given once every 3 weeks
  o Paclitaxel, given once a week for 3 out of every 4 weeks

  People will receive their assigned treatment through a needle into a vein. People will continue their treatment until the cancer gets worse or the person doesn’t tolerate treatment.

  The people in the study and the researcher will know which study treatment a person is getting. During the study, people may give urine and blood samples, have tumour and imaging tests, have physical examinations, and answer sets of questions about how they are feeling and their ability to carry out daily tasks.

  A person may be in this study for about 4 years.

• REC name

  North East - York Research Ethics Committee

• REC reference

  23/NE/0191

• Date of REC Opinion

  3 Jan 2024

• REC opinion

  Further Information Favourable Opinion